IP Library Granted Patent US 9,884,127
Granted Patent B2
US 9,884,127 · App. 14/401,114 · Granted Feb 6, 2018

Drug-conjugates, conjugation methods, and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,127
App. No.
14/401,114
Granted
Feb 6, 2018
Kind
B2
Abstract

In one aspect, an active agent-conjugate, methods of preparing the active agent-conjugate, and uses thereof is provided.

Claims (21)

1. An active agent-conjugate composition comprising Formula 1a:

or a pharmaceutically acceptable salt thereof,

wherein:

the A-component is an antibody or an antibody fragment comprising a heavy and light chain;

the E-component is selected from the group consisting of:

L 3 is an optionally substituted C 1 -C 6 alkyl, or L 3 is null, when L 3 is null the sulfur is directly connected to the E-component;

L 4 is an optionally substituted C 1 -C 6 alkyl, or L 4 is null, when L 4 is null the sulfur is directly connected to the E-component;

B is a monoclonal antibody or peptide;

each D is independently selected, wherein each D includes an active agent;

each L 2 is independently a linker, wherein L 2 links to E; and

n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

2. The active agent-conjugate of claim 1 , wherein L 3 is —(CH 2 )—; and L 4 is —(CH 2 )—.

3. The active agent-conjugate of claim 1 , wherein L 3 is null; and L 4 is null.

4. The active agent-conjugate of claim 1 , wherein:

is selected from the group consisting of:

5. The active agent-conjugate of claim 1 , wherein said active agent is independently selected from the group consisting of tubulin binders, DNA alkylators, DNA intercalators, enzyme inhibitors, and immune modulators.

6. The active agent-conjugate of claim 1 , wherein the structure of Formula Ia has a structure selected from the group consisting of:

7. The active agent-conjugate of claim 1 , wherein L 2 is a peptide or an oligosaccharide.

8. The active agent-conjugate of claim 1 , wherein the A component comprises at least one modified L-Alanine residue.

9. The active agent-conjugate of claim 1 , wherein said active agent is independently selected from peptides and nucleotides.

10. The active agent-conjugate of claim 1 , wherein L 2 is selected from the group consisting of —(CH 2 ) n —, —(CH 2 CH 2 O) n —, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, Ala-PAB, and PAB.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2024
From: SORRENTO THERAPEUTICS, INC.
To: VIVASOR, INC.
Reel/Frame 067529/0019 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2020
From: OAKTREE FUND ADMINISTRATION, LLC
To: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 053368/0577 →
SECURITY INTEREST Recorded Nov 7, 2018
From: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 047446/0335 →